{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-26-000024","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.806712+00:00","generated_at":"2026-05-15T17:54:29.293103+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Keros collaborates with Mass General on Phase 2 ALS trial of rinvatercept; presents new Phase 1 data at MDA Conf.","bullets":["Entered agreement with Massachusetts General Hospital for Phase 2 ALS trial within HEALEY ALS MyMatch program.","Additional Phase 1 data presented at 2026 MDA Conference: rinvatercept generally well-tolerated with no serious adverse events.","Phase 1 data showed increased muscle mass, decreased fat mass, and increased bone mineral density in healthy volunteers.","Proteomic analysis confirmed target engagement and anti-fibrotic/anti-inflammatory effects consistent with activin inhibition.","Keros plans two Phase 2 trials: one in Duchenne muscular dystrophy (DMD) and one in ALS."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-26-000024","json":"https://secwatch.observer/filing/0001664710-26-000024.json","markdown":"https://secwatch.observer/filing/0001664710-26-000024.md","text":"https://secwatch.observer/filing/0001664710-26-000024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000024/0001664710-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471026000024/kros-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:54:29.293103+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}